Price
$0.32
Decreased by -5.61%
Dollar volume (20D)
21.93 K
ADR%
10.21
Earnings report date
Aug 7, 2024
Shares float
5.79 M
Shares short
23.80 K [0.41%]
Shares outstanding
6.36 M
Market cap
2.02 M
Beta
0.80
Price/earnings
N/A
20D range
0.31 0.41
50D range
0.31 0.44
200D range
0.26 0.90

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.

Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis.

It has a license agreement with Samil Pharma.

Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.

Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 30, 24 -0.98
Increased by +10.09%
-0.32
Decreased by -206.25%
Mar 29, 24 -0.98
Decreased by -880.00%
-0.32
Decreased by -206.25%
Nov 22, 23 -0.24
Decreased by -14.29%
-0.27
Increased by +11.11%
Aug 9, 23 -0.95
Decreased by -533.33%
-0.34
Decreased by -179.41%
Jun 1, 23 -1.09
Decreased by -263.33%
-1.50
Increased by +27.33%
Mar 29, 23 -0.10
Increased by +66.67%
-0.14
Increased by +28.57%
Nov 16, 22 -0.21
Increased by +32.26%
-0.16
Decreased by -31.25%
Aug 4, 22 -0.15
Increased by +54.55%
-0.24
Increased by +37.50%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 N/A
Decreased by N/A%
-2.02 M
Decreased by -21.59%
- -
Dec 31, 23 0.00
Decreased by N/A%
-2.02 M
Increased by +28.74%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-1.47 M
Increased by +72.62%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-1.59 M
Increased by +57.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-1.66 M
Increased by +77.75%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-2.83 M
Increased by +62.04%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-5.38 M
Increased by +30.26%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-3.73 M
Increased by +55.57%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY